Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Lowered by StockNews.com

StockNews.com downgraded shares of Collegium Pharmaceutical (NASDAQ:COLL) from a strong-buy rating to a buy rating in a research report released on Wednesday morning.

A number of other research analysts have also issued reports on COLL. Truist Financial lifted their target price on Collegium Pharmaceutical from $40.00 to $42.00 and gave the stock a “buy” rating in a report on Friday, August 9th. HC Wainwright lifted their target price on Collegium Pharmaceutical from $47.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, September 5th. Piper Sandler reaffirmed a “neutral” rating and set a $37.00 target price on shares of Collegium Pharmaceutical in a report on Friday, October 11th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Collegium Pharmaceutical in a report on Friday, August 9th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and an average target price of $42.60.

Collegium Pharmaceutical Price Performance

Shares of NASDAQ COLL opened at $34.70 on Wednesday. Collegium Pharmaceutical has a fifty-two week low of $20.95 and a fifty-two week high of $42.29. The firm’s 50-day simple moving average is $37.66 and its 200 day simple moving average is $35.32. The company has a quick ratio of 1.04, a current ratio of 1.11 and a debt-to-equity ratio of 1.71. The stock has a market cap of $1.14 billion, a P/E ratio of 14.46 and a beta of 0.94.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.22. Collegium Pharmaceutical had a net margin of 17.32% and a return on equity of 107.62%. The business had revenue of $145.28 million for the quarter, compared to analysts’ expectations of $143.94 million. During the same period in the previous year, the business earned $1.13 earnings per share. The company’s revenue was up 7.2% on a year-over-year basis. Equities analysts expect that Collegium Pharmaceutical will post 5.79 EPS for the current year.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 19,248 shares of Collegium Pharmaceutical stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total value of $737,198.40. Following the transaction, the executive vice president now owns 120,161 shares of the company’s stock, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 19,248 shares of the firm’s stock in a transaction dated Thursday, September 5th. The stock was sold at an average price of $38.30, for a total transaction of $737,198.40. Following the completion of the sale, the executive vice president now directly owns 120,161 shares in the company, valued at approximately $4,602,166.30. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Thomas B. Smith sold 9,593 shares of the firm’s stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $36.62, for a total value of $351,295.66. Following the sale, the executive vice president now owns 53,816 shares of the company’s stock, valued at $1,970,741.92. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.98% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

A number of institutional investors have recently bought and sold shares of COLL. Gladius Capital Management LP acquired a new stake in Collegium Pharmaceutical during the 2nd quarter worth about $32,000. nVerses Capital LLC boosted its position in Collegium Pharmaceutical by 1,600.0% during the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 1,600 shares during the period. GAMMA Investing LLC boosted its position in Collegium Pharmaceutical by 124.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,428 shares of the specialty pharmaceutical company’s stock worth $55,000 after acquiring an additional 792 shares during the period. CWM LLC boosted its position in Collegium Pharmaceutical by 97.5% during the 3rd quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after acquiring an additional 736 shares during the period. Finally, Sheaff Brock Investment Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the 1st quarter valued at about $204,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.